Your browser is no longer supported. Please, upgrade your browser.
PainReform Ltd.
Index- P/E- EPS (ttm)- Insider Own63.79% Shs Outstand8.91M Perf Week8.25%
Market Cap56.13M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float0.21M Perf Month28.31%
Income- PEG- EPS next Q- Inst Own12.22% Short Float13.30% Perf Quarter37.25%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.10 Perf Half Y-
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range3.82 - 7.85 Perf YTD40.94%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-19.75% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low64.92% ATR0.73
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)60.99 Volatility15.84% 14.45%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.69 Prev Close6.50
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume290.28K Price6.30
Recom- SMA2017.59% SMA5030.39% SMA20029.19% Volume201,965 Change-3.08%
Jan-07-21 08:30AM  
Jan-06-21 08:30AM  
Jan-04-21 08:30AM  
Nov-23-20 08:30AM  
Nov-12-20 09:00AM  
Nov-05-20 08:30AM  
Oct-19-20 09:00AM  
Sep-29-20 07:30AM  
Sep-09-20 02:15PM  
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of products for the treatment of pain in Israel. It develops PRF-110, a product based on local anesthetic ropivacaine, which completed Phase II clinical study in hernia repair. The company was founded in 2007 and is headquartered in Herzeliya, Israel.